Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RXi Pharmaceuticals, a discovery-stage biopharmaceutical company and miRagen Therapeutics, a biopharmaceutical company focused on developing microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, have entered into a research collaboration.
Subscribe to our email newsletter
As per the agreement, the parties are expected to evaluate the potential utility of RXi’s proprietary rxRNA technology against specific miRNA targets of interest to miRagen in the cardiac and neuromuscular disease areas.
Additionally, each party will contribute its technology and resources to the collaboration to generate novel miRNA compounds. Financial terms of the collaboration were not disclosed.
Noah Beerman, president and CEO of Rxi Pharmaceuticals, said: “We look forward to working with miRagen in exploring the potential of validating our proprietary rxRNA compounds in the field of miRNA, as success with this approach may allow us to expand the utility of RXi’s therapeutic platform, as well as the commercial scope of product opportunities.“
William Marshall, president and CEO of miRagen Therapeutics, said: “miRagen is committed to evaluating and deploying the most advanced technologies available to support our mission of developing microRNA-based therapeutics. We are enthusiastic about the potential for the rxRNA technology to produce miRNA mimicry and thus are keenly interested in working with RXi to further investigate its properties.”